



## Periprosthetic Joint Infections: Pathomechanism, Diagnostics and Novel Treatment Options

Guest Editor:

### Dr. Jochen Hofstaetter

1. Orthopaedic Hospital Vienna  
Speising, Vienna, Austria  
2. Michael Ogon Laboratory for  
Orthopaedic Research,  
Orthopaedic Hospital Vienna  
Speising, Vienna, Austria

Deadline for manuscript  
submissions:

**closed (31 March 2022)**

### Message from the Guest Editor

Periprosthetic joint infection (PJI) following total hip or knee arthroplasty is a serious complication with high morbidity and mortality. Its reported incidence is up to 2% in primary and up to 15% in revision cases. Due to the expected rising numbers of primary and revision arthroplasties performed over the next decades, we subsequently will see a dramatic increase in PJI's. Unfortunately, we have not made great progress in the prevention and treatment of PJI's in recent time. Therefore we need to increase our research effort in order to improve our clinical results. PJI is complex multifactorial interdisciplinary problem. The aim of this special issue is to illustrate the complexity of PJI and the following topics are welcome

1. Prevention of PJI in hip and knee arthroplasty
2. Polymicrobial infections, antimicrobial resistance, low grade infections
3. Biofilm
4. Novel approaches in diagnosis and treatment

The focus of *Biomedicine* is directed towards genetic mechanisms and molecular and pathological characteristics and their translation to medicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI